消疹止痒喷剂治疗表皮生长因子受体抑制剂相关性皮疹的临床观察
发布时间：2018-12-19 15:51
【摘要】：目的:观察消疹止痒喷剂治疗表皮生长因子受体抑制剂(EGFRI)相关性皮疹的临床疗效及安全性。方法:选择2015年5月-2016年5月于我院肿瘤科确诊为恶性肿瘤、接受EGFRI治疗后出现皮疹的患者60例,按患者用药意愿分成试验组(40例)和对照组(20例)。对照组患者不采取任何药物治疗皮疹;试验组患者使用消疹止痒喷剂喷患处,治疗频次由医师根据皮疹分级确定为1级1~2次/d、2级2~3次/d、3级3~5次/d,共治疗2周。比较两组患者治疗前后的皮疹分级及改善情况、瘙痒分级及改善情况、生活质量指标调查表(DLQI)评分,以及不良反应发生情况。结果:治疗前,两组患者的皮疹和瘙痒分级情况,以及DLQI评分比较,差异均无统计学意义(P0.05)。治疗后,试验组患者的皮疹和瘙痒分级情况较本组治疗前及对照组均显著好转,差异有统计学意义(P0.05);试验组患者的皮疹治疗总有效率(67.50%)、瘙痒治疗总有效率(70.00%)均显著高于对照组(分别为20.00%、15.00%),差异均有统计学意义(P0.05)。试验组患者的DLQI评分显著低于本组治疗前及对照组,差异均有统计学意义(P0.05);对照组患者治疗前后的DLQI评分比较,差异无统计学意义(P0.05)。试验组患者未见明显不良反应发生。结论:消疹止痒喷剂能有效缓解EGFRI相关性皮疹症状,减轻瘙痒感,提高患者生活质量。
[Abstract]:Objective: to observe the clinical efficacy and safety of Xiaorash antipruritic spray in the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated rash. Methods: from May 2015 to May 2016, 60 cases of malignant tumor diagnosed in our department of oncology were divided into experimental group (n = 40) and control group (n = 20). The patients in the control group did not take any drugs to treat the rash, and the patients in the trial group were treated with antipruritic spray. The treatment frequency was determined by the physician to be 1 / 2 / d / 2 / d / 3 / 3 / 3 / d, 5 times / d for 2 weeks. The grade and improvement of rash, the classification and improvement of pruritus, the (DLQI) score of quality of life questionnaire, and the occurrence of adverse reactions were compared between the two groups before and after treatment. Results: before treatment, there was no significant difference in rash and pruritus grading and DLQI score between the two groups (P0.05). After treatment, the rashes and itching grading of the patients in the experimental group were significantly improved compared with those before treatment and the control group, the difference was statistically significant (P0.05). The total effective rate of skin rash treatment (67.50%) and the total effective rate of pruritus treatment (70.00%) in the trial group were significantly higher than those in the control group (20.00% 15.00%), the difference was statistically significant (P0.05). The DLQI score of the patients in the trial group was significantly lower than that before the treatment and the control group, the difference was statistically significant (P0.05); the DLQI score of the patients in the control group was not significantly different before and after treatment (P0.05). No significant adverse reactions were observed in the trial group. Conclusion: Xiaorash and itching spray can effectively relieve the symptoms of EGFRI associated rash, relieve pruritus and improve the quality of life of patients.
【作者单位】： 苏州大学附属第一医院药学部;苏州大学附属第一医院肿瘤科;
【基金】：江苏省中医药科技项目(No.YB2015175) 苏州市科技发展计划项目(No.SYSD2014144)
【分类号】：R758.25
本文编号：2387132
[Abstract]:Objective: to observe the clinical efficacy and safety of Xiaorash antipruritic spray in the treatment of epidermal growth factor receptor inhibitor (EGFRI) associated rash. Methods: from May 2015 to May 2016, 60 cases of malignant tumor diagnosed in our department of oncology were divided into experimental group (n = 40) and control group (n = 20). The patients in the control group did not take any drugs to treat the rash, and the patients in the trial group were treated with antipruritic spray. The treatment frequency was determined by the physician to be 1 / 2 / d / 2 / d / 3 / 3 / 3 / d, 5 times / d for 2 weeks. The grade and improvement of rash, the classification and improvement of pruritus, the (DLQI) score of quality of life questionnaire, and the occurrence of adverse reactions were compared between the two groups before and after treatment. Results: before treatment, there was no significant difference in rash and pruritus grading and DLQI score between the two groups (P0.05). After treatment, the rashes and itching grading of the patients in the experimental group were significantly improved compared with those before treatment and the control group, the difference was statistically significant (P0.05). The total effective rate of skin rash treatment (67.50%) and the total effective rate of pruritus treatment (70.00%) in the trial group were significantly higher than those in the control group (20.00% 15.00%), the difference was statistically significant (P0.05). The DLQI score of the patients in the trial group was significantly lower than that before the treatment and the control group, the difference was statistically significant (P0.05); the DLQI score of the patients in the control group was not significantly different before and after treatment (P0.05). No significant adverse reactions were observed in the trial group. Conclusion: Xiaorash and itching spray can effectively relieve the symptoms of EGFRI associated rash, relieve pruritus and improve the quality of life of patients.
【作者单位】： 苏州大学附属第一医院药学部;苏州大学附属第一医院肿瘤科;
【基金】：江苏省中医药科技项目(No.YB2015175) 苏州市科技发展计划项目(No.SYSD2014144)
【分类号】：R758.25
【相似文献】
相关期刊论文 前1条
1 陆富永;明海霞;尹仲;刘懿;马兰;周宁;李艳芸;;瑞美科皮肤粘膜抗菌护理喷剂对尖锐湿疣电灼术后创面的影响[J];中国现代医药杂志;2011年12期
，本文编号：2387132
本文链接：https://www.wllwen.com/yixuelunwen/pifb/2387132.html
最近更新
教材专著
